Discovery Capital Management’s Cardlytics CDLX Stock Holding History

Discovery Capital Management’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,000	Closed	-$1.68M	–	73
2021 Q3	$1.68M	Sell	2,000 -1,000	-33%	-$1.01M	0.13%	66
2021 Q2	$3.81M	Sell	3,000 -2,000	-40%	-$2.26M	0.25%	45
2021 Q1	$5.49M	Buy	+5,000	New	+$6.6M	0.74%	32
2019 Q1	–	Sell	-42,857	Closed	-$4.64M	–	37
2018 Q4	$4.64M	Buy	42,857 +10,888	+34%	+$1.84M	0.39%	37
2018 Q3	$8.01M	Sell	31,969 -118,506	-79%	-$25.5M	0.48%	39
2018 Q2	$31.2M	Hold	150,475	–	–	1.69%	23
2018 Q1	$20.5M	Buy	+150,475	New	+$25.5M	0.72%	36

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Discovery Capital Management's CDLX Position: Q4 2021 in Review

Discovery Capital Management sold out of Cardlytics (CDLX) in Q4 2021, closing a stake of 2,000 shares — an estimated $1.68M sold.

Discovery Capital Management first reported a position in CDLX in Q1 2018 and held it in 7 quarters. The position peaked at $31.2M in Q2 2018. 163 funds tracked by Wall St. Rank hold CDLX as of Q4 2021.

Discovery Capital Management reported no remaining Cardlytics position as of Q4 2021 after selling out during the quarter.
Discovery Capital Management sold 2,000 Cardlytics shares in Q4 2021, an estimated $1.68M.
Discovery Capital Management first reported a position in Cardlytics in Q1 2018 and held it in 7 quarters.
Discovery Capital Management's Cardlytics position peaked at $31.2M in Q2 2018.
163 funds tracked by Wall St. Rank held Cardlytics as of Q4 2021.

Based on Discovery Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.